ABOUT BIORASI

Biorasi is an award-winning contract research organization accelerating drug and device clinical development for life sciences companies around the world.  Since 2002, Biorasi has achieved success in bringing innovative therapies to market for our sponsors. Biorasi solves the problem of poor clinical trial performance with better patient recruitment, powerful data insights, and operational excellence. We deliver faster, higher quality clinical trials. Biorasi is headquartered in Miami, Florida, and has regional offices around the globe.

FEATURED PRODUCTS/SERVICES

The biggest issues for faltering trials? Incomplete planning and enrollment issues  can explode into big problems if not addressed early enough. Biorasi offers a no-commitment, no-charge, fast consulting assessment that will identify and correct these issues in your study early – before they grow too big to manage.

CONTACT INFORMATION

Biorasi

19495 Biscayne Blvd. Suite 900

Miami, FL 33180

UNITED STATES

Phone: 786 388 0700

Contact: Nadine Alam

BLOGS

  • While there are socioeconomic factors contributing to the reasons behind the lack of diversity, the exclusion of minority populations in clinical trials can be a scientifically flawed misstep. By focusing on a single demographic, clinical research findings become limited, and by ignoring other representative populations ‘unexpected’ side effects may be more commonplace while treatment success levels will vary.

  • Cell therapy has moved beyond “science fiction” and into effective FDA-approved treatment for three key hematological cancers. Hematologist Dr. Robert S. Negrin takes a deeper dive into identifying and understanding the central differentiators in cell therapy clinical trials.

  • Alzheimer’s Disease currently afflicts close to 50 million people worldwide, highlighting the importance of clinical trials for this condition. Alzheimer’s studies are unique in that they require an additional participant to assess the patient’s mental and physical health during the trial. But what are the characteristics of a viable study partner?

  • Oncology trials may start out similarly to other therapeutic indications, but they differ radically in relation to early phases of the study, biomarkers, drug characteristics, and competition for patients.  In this article, Dr. Alex Adjei speaks about the top four differentiators in oncology studies that make them unique among other trials.

  • Diagnostics and treatment for Alzheimer’s Disease vary – both around the world and around the block. In this article read how recognizing the common disparities for these clinical trials, ranging from standards of care to lack of diversity, brings sponsors and other stakeholders closer to maintaining standardized protocols for Alzheimer’s studies.

  • Clinical sites that have a great deal of experience are generally sought after, but can often be busy running other trials. It may be beneficial to consider less experienced sites in order to have more trial options. But of course, there are some necessary considerations when turning to these sites.

WHITE PAPERS & CASE STUDIES

  • While there are socioeconomic factors contributing to the reasons behind the lack of diversity, the exclusion of minority populations in clinical trials can be a scientifically flawed misstep. By focusing on a single demographic, clinical research findings become limited, and by ignoring other representative populations ‘unexpected’ side effects may be more commonplace while treatment success levels will vary.

  • Cell therapy has moved beyond “science fiction” and into effective FDA-approved treatment for three key hematological cancers. Hematologist Dr. Robert S. Negrin takes a deeper dive into identifying and understanding the central differentiators in cell therapy clinical trials.

  • Alzheimer’s Disease currently afflicts close to 50 million people worldwide, highlighting the importance of clinical trials for this condition. Alzheimer’s studies are unique in that they require an additional participant to assess the patient’s mental and physical health during the trial. But what are the characteristics of a viable study partner?

  • Oncology trials may start out similarly to other therapeutic indications, but they differ radically in relation to early phases of the study, biomarkers, drug characteristics, and competition for patients.  In this article, Dr. Alex Adjei speaks about the top four differentiators in oncology studies that make them unique among other trials.

  • Diagnostics and treatment for Alzheimer’s Disease vary – both around the world and around the block. In this article read how recognizing the common disparities for these clinical trials, ranging from standards of care to lack of diversity, brings sponsors and other stakeholders closer to maintaining standardized protocols for Alzheimer’s studies.

  • Clinical sites that have a great deal of experience are generally sought after, but can often be busy running other trials. It may be beneficial to consider less experienced sites in order to have more trial options. But of course, there are some necessary considerations when turning to these sites.

  • The spread of COVID-19 has heightened the potential risk of infection for patients suffering from blood disorders. Hematologist Dr. Robert S. Negrin, a new member of Biorasi’s growing Scientific Advisory Board, weighs in on understanding and adapting to changes to blood disorder trials and treatment during the pandemic.

  • Paroxysmal nocturnal hemoglobinuria (PNH) is defined as an acquired rare disease triggered by a rare mutation in bone marrow stem cells, with patients experiencing production of irregular blood cells. In terms of clinical studies, PNH’s uniqueness presents a number of operational challenges. In this article, Dr. Mehool Patel discusses innovations in the treatment of PNH, the diverse nature of this rare disease, as well as solutions for PNH clinical trial enrollment and availability.

NEWS

  • Biorasi Joins Nova Southeastern University To Spur Healthcare Job Growth In South Florida
    9/8/2018

    Biorasi, a leading full-service global contract research organization (CRO), is excited to announce two new certificate programs through Nova Southeastern University to provide targeted education and job skills for future healthcare workers in South Florida.  The certificate programs are a joint effort between the two organizations to create a Clinical Research Associate (CRA) graduate certificate program through the university’s Dr. Pallavi Patel College of Health Care Sciences. This certificate program will help prepare students to enter the rapidly growing field of clinical research and provide them with the practical skills and knowledge to secure employment in a well-paying career in the sciences.